Sara H Ksiazek, Lilio Hu, Sebastiano Andò, Markus Pirklbauer, Marcus D Säemann, Chiara Ruotolo, Gianluigi Zaza, Gaetano La Manna, Luca De Nicola, Gert Mayer, Michele Provenzano
Renin-angiotensin-aldosterone system (RAAS) inhibitors are standard care in patients with hypertension, heart failure or chronic kidney disease (CKD). Although we have studied the RAAS for decades, there are still circumstances that remain unclear. In this review, we describe the evolution of the RAAS and pose the question of whether this survival trait is still necessary to humankind in the present age. We elucidate the benefits on cardiovascular health and kidney disease of RAAS inhibition and present promising novel medications...
April 4, 2024: International Journal of Molecular Sciences